Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
ASCO Endorses EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer
Clin Oncol; ePub 2016 Mar 21; Milowsky, Rumble, et al
An ASCO panel has endorsed the recommendations of the European Association of Urology on muscle-invasive (MIBC) and metastatic bladder cancer. The guideline recommends:
• Multidisciplinary care for patients with MIBC and metastatic bladder cancer is critical.
• The standard treatment of MIBC (cT2-T4a N0M0) is neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy.
• In cisplatin-ineligible patients, radical cystectomy alone is recommended.
• Adjuvant cisplatin-based chemotherapy may be offered to high-risk patients who have not received neoadjuvant therapy.
• Chemoradiotherapy may be offered as an alternative to cystectomy in appropriately selected patients with MIBC and in some patients for whom cystectomy is not an option.
• Metastatic disease should be treated with cisplatin-containing combination chemotherapy or with carboplatin combination chemotherapy or single agents in patients ineligible for cisplatin.
Citation: Milowsky MI, Rumble RB, Booth CM, et al. Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology guideline): American Society of Clinical Oncology Clinical Practice guideline endorsement. [Published online ahead of print March 21, 2016]. Clin Oncol. doi:10.1200/JCO.2015.65.9797.